DE3485649D1 - Verfahren zur herstellung von antikoerperzusammensetzungen von therapeutischen mitteln mit verlaengerter serumhalbwertzeit. - Google Patents

Verfahren zur herstellung von antikoerperzusammensetzungen von therapeutischen mitteln mit verlaengerter serumhalbwertzeit.

Info

Publication number
DE3485649D1
DE3485649D1 DE8484306027T DE3485649T DE3485649D1 DE 3485649 D1 DE3485649 D1 DE 3485649D1 DE 8484306027 T DE8484306027 T DE 8484306027T DE 3485649 T DE3485649 T DE 3485649T DE 3485649 D1 DE3485649 D1 DE 3485649D1
Authority
DE
Germany
Prior art keywords
serum half
value
therapeutic agents
antibody compositions
producing antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8484306027T
Other languages
English (en)
Inventor
James M Frincke
Barbara W Unger
Karen G Burnett
Evan Myron Hersh
Michael Gordon Rosenblum
Jordan Udell Gutterman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Application granted granted Critical
Publication of DE3485649D1 publication Critical patent/DE3485649D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
DE8484306027T 1983-09-01 1984-09-03 Verfahren zur herstellung von antikoerperzusammensetzungen von therapeutischen mitteln mit verlaengerter serumhalbwertzeit. Expired - Fee Related DE3485649D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB08323428A GB2148299B (en) 1983-09-01 1983-09-01 Antibody compositions of therapeutic agents having an extended serum half-life

Publications (1)

Publication Number Publication Date
DE3485649D1 true DE3485649D1 (de) 1992-05-21

Family

ID=10548161

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8484306027T Expired - Fee Related DE3485649D1 (de) 1983-09-01 1984-09-03 Verfahren zur herstellung von antikoerperzusammensetzungen von therapeutischen mitteln mit verlaengerter serumhalbwertzeit.

Country Status (11)

Country Link
US (1) US5055289A (de)
EP (1) EP0136835B1 (de)
JP (1) JPH0717519B2 (de)
AT (1) ATE74766T1 (de)
AU (1) AU593208B2 (de)
CA (1) CA1249222A (de)
DE (1) DE3485649D1 (de)
DK (1) DK191985A (de)
FI (1) FI85441C (de)
GB (1) GB2148299B (de)
WO (1) WO1985000974A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US5009888A (en) * 1987-04-13 1991-04-23 Genzyme Corporation Therapeutic enzyme-antibody complexes
EP0298654B1 (de) * 1987-07-07 1994-06-01 Hybrisens Ltd. Verwendung von Antikörper-Antigen-Wechselwirkung zum Schutz oder Modulation der biologischen Aktivität
WO1989006544A1 (en) * 1988-01-15 1989-07-27 Centocor, Inc. Heteroligating antibodies and therapeutic uses thereof
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5225540A (en) * 1988-04-26 1993-07-06 Du Pont Merck Pharmaceutical Company Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life
GB8813527D0 (en) * 1988-06-08 1988-07-13 Glennie M J Bispecific antibodies
US5686579A (en) * 1988-06-21 1997-11-11 Hybrisens, Ltd. Use of antibody/antigen interactions to protect biologically active proteins and peptides
WO1989012463A1 (en) * 1988-06-21 1989-12-28 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
IE62463B1 (en) * 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5760203A (en) * 1988-08-10 1998-06-02 Chiron Corporation Gap gene sequences
US5763573A (en) * 1988-08-10 1998-06-09 Chiron Corporation GTPase activating protein fragments
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
KR900005995A (ko) * 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
IE63847B1 (en) * 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DE69102265T2 (de) * 1990-02-06 1994-10-13 Takeda Chemical Industries Ltd Immunkomplexe.
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
AU696560B2 (en) * 1993-03-19 1998-09-10 Fred D. Finkelman Pharmaceutical compositions comprising a ligand complexed with a soluble receptor
US20030017147A1 (en) * 1996-09-20 2003-01-23 Guy L Reed Composition and method for enhancing fibrinolysis
US6313089B1 (en) 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
JP2001518449A (ja) * 1997-09-30 2001-10-16 デューク・ユニバーシティー アポリポタンパク質ｅ／成長因子複合体およびその使用法
CN101612402A (zh) * 2001-01-09 2009-12-30 贝勒研究院 干扰素拮抗剂和Flt3L拮抗剂的用途
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
AU2002327310B2 (en) 2001-07-17 2006-09-28 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
CA2464271A1 (en) * 2001-10-22 2003-05-01 The Scripps Research Institute Integrin targeting compounds
JP4750360B2 (ja) * 2001-10-22 2011-08-17 ザ スクリプス リサーチ インスティチュート 抗体ターゲッティング化合物
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US20070298041A1 (en) * 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
EP1900753B1 (de) 2002-11-08 2017-08-09 Ablynx N.V. Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
EP1426382A1 (de) * 2002-12-06 2004-06-09 Aventis Behring GmbH Antivirales menschliches Serum Albumin
CA2561732A1 (en) * 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited Antibody drug
EP2286835A1 (de) * 2004-10-07 2011-02-23 Universität Zürich Prorektorat Forschung Typ 1 Interferon Antagonisten zur Vorbeugung und Behandlung von Psoriasis
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
JP2008521870A (ja) * 2004-12-02 2008-06-26 ドマンティス リミテッド 抗ｉｌ−１ｒ１単一ドメイン抗体および治療使用
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
WO2006086586A2 (en) 2005-02-10 2006-08-17 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
AU2006321364B2 (en) * 2005-12-01 2011-11-10 Domantis Limited Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
JP2009517069A (ja) * 2005-12-01 2009-04-30 ドマンティス リミテッド インターロイキン１受容体１型に結合する競合ドメイン抗体フォーマット
EA200901494A1 (ru) * 2007-06-06 2010-06-30 Домантис Лимитед Способы селекции протеазоустойчивых полипептидов
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
MX2010012052A (es) 2008-05-07 2010-12-14 Novo Nordisk As Anticuerpos humanizados contra interferon-alfa humano.
DK2613776T3 (da) 2010-09-01 2020-10-19 Univ Jefferson Sammensætning og fremgangsmåde til muskelreparation og -regenerering
EP2537933A1 (de) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine
JP6184965B2 (ja) 2011-10-28 2017-08-23 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ポリペプチド構築物およびその使用
CN109395064A (zh) 2013-04-19 2019-03-01 赛腾制药 降低的血管渗漏综合征的细胞因子衍生治疗
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
AU2013388126B2 (en) 2013-04-29 2019-03-07 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b
CA2931299C (en) 2013-11-20 2024-03-05 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof
EP2915569A1 (de) 2014-03-03 2015-09-09 Cytune Pharma Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EP3212216A4 (de) 2014-10-29 2018-04-18 Teva Pharmaceuticals Australia Pty Ltd Varianten von interferon alpha2b
JP2019131471A (ja) * 2016-05-27 2019-08-08 国立大学法人 東京大学 抗ＴＧＦ−ｂｅｔａ３抗体およびその使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509707A (en) * 1974-09-20 1978-05-04 Searle & Co Immunological compounds
US4195017A (en) * 1975-02-25 1980-03-25 Samuel Bogoch Malignin, derived from brain tumor cells, complexes and polypeptides thereof
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
US4263279A (en) * 1975-08-19 1981-04-21 Yeda Research & Development Co. Ltd Pharmaceutically active compositions containing adriamycin and daunomycin
GB1564666A (en) * 1978-05-31 1980-04-10 Ng Mun Hon Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS5616417A (en) * 1979-07-19 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
US4423147A (en) * 1980-04-11 1983-12-27 Secher David S Monoclonal antibody to interferon-α
EP0044167A3 (de) * 1980-07-14 1982-04-21 The Regents Of The University Of California Durch einen Antikörper gerichtetes zytotoxisches Mittel
US4359457A (en) * 1980-09-30 1982-11-16 Neville Jr David M Anti Thy 1.2 monoclonal antibody-ricin hybrid utilized as a tumor suppressant
FI820020L (fi) * 1981-01-12 1982-07-13 Lilly Industries Ltd Immunoglobulinkonjugater
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
GB2098219A (en) * 1981-05-08 1982-11-17 Erba Farmitalia Daunorubicin-protein conjugates
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
CA1213229A (en) * 1982-04-12 1986-10-28 Gary S. David Antibodies having dual specificities, their preparation and uses therefor
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
DE3483385D1 (de) * 1983-08-17 1990-11-15 Wellcome Found Physiologisch aktive zusammensetzungen.

Also Published As

Publication number Publication date
AU3393584A (en) 1985-03-29
CA1249222A (en) 1989-01-24
DK191985D0 (da) 1985-04-29
JPS60502104A (ja) 1985-12-05
EP0136835A3 (en) 1986-10-08
GB2148299A (en) 1985-05-30
WO1985000974A1 (en) 1985-03-14
US5055289A (en) 1991-10-08
FI85441C (fi) 1992-04-27
GB2148299B (en) 1988-01-06
FI851635L (fi) 1985-04-25
FI85441B (fi) 1992-01-15
DK191985A (da) 1985-04-29
AU593208B2 (en) 1990-02-08
EP0136835A2 (de) 1985-04-10
JPH0717519B2 (ja) 1995-03-01
GB8323428D0 (en) 1983-10-05
EP0136835B1 (de) 1992-04-15
FI851635A0 (fi) 1985-04-25
ATE74766T1 (de) 1992-05-15

Similar Documents

Publication Publication Date Title
DE3485649D1 (de) Verfahren zur herstellung von antikoerperzusammensetzungen von therapeutischen mitteln mit verlaengerter serumhalbwertzeit.
ATE160583T1 (de) Steigerungsverfahren der transmembranförderung von exogenen molekülen
ATE16567T1 (de) Intravenoes injektierbares globulin aus immunserum und verfahren zu seiner herstellung.
DD128170A5 (de) Verfahren zur herstellung von praeparaten mit geregelter wirkstoffabgabe
DD129788A5 (de) Verfahren zur herstellung von 3',3'',5',5''-tetrachlorphenol-3,4,5,6-tetrabromsulfophthalein bzw.3',3''-dibrom-5',5''-dichlorphenol-3,4,5,6-tetrachlorsulfophthalein
DE3486232D1 (de) Verfahren zur Herstellung von L-Arginin.
ATE866T1 (de) Immunserumglobulin (isg)-praeparate und verfahren zu ihrer herstellung.
AT339267B (de) Verfahren zur selektiven herstellung von alkyl-tert.butylathern
ATA395576A (de) Verfahren zur herstellung von nicht mehr antikomplementaer wirksamen nativ-human- -immunglobulin zur intravenoesen verabreichung mit natuerlicher halbwertszeit
AT371795B (de) Verfahren zur herstellung von tert.olefinen
SE7609055L (sv) Veterinerkompositioner
DE68921582D1 (de) Verfahren zur Herstellung von funktionellen Isothiocyanatometallkomplexen.
JPS5547627A (en) Manufacture of immune globulin solution good for intravenous application
DK398483D0 (da) Substiuerede tert.butanolderivater, fremgangsmader til fremstilling deraf samt antimykotiske midler indeholdende disse forbindelser
DE69020556D1 (de) Verfahren zur herstellung von therapeutischen rhenium-phosphonat-mitteln.
DD129979A5 (de) Verfahren zur herstellung von polyjodderivaten von benzol
ES386714A1 (es) Procedimiento para la preparacion de nuevos derivados de tiepina.
RO82171A (ro) Procedeu pentru prepararea dimerului vinca
JPS5257108A (en) Process for optical active aldehydes
ES381207A1 (es) Un procedimiento para preparar nuevas 1,2-difenil-3,5-dioxo-pirazolidinas sustituidas en la posicion 4.
JPS5283912A (en) Fat emulsion for intravenous injection
DD128525A5 (de) Verfahren zur herstellung von 1,2,3,4-tetrahydro-4-oxo-(oder-oxy-)-1-naphthylharnstoffen
ES8505513A1 (es) Procedimiento para la fabricacion de aminoacetonitrilos.
ES191162U (es) Juguete de composicion.
NL7510321A (nl) Werkwijze voor de bereiding van 6-(n-beschermd amino)-2,2-dimethyl-3-(5-tetrazolyl)penamverbin- dingen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee